MyFinsight
Home
Blog
About
Contact
Proceeds from exercise of
tranche a warrants
$1,200,000
Net cash provided by
financing activities
$1,079,125
Canceled cashflow
$120,875
Net decrease in
cash, cash...
-$49,642,043
Canceled cashflow
$1,079,125
Changes in fair value of
the warrant...
$109,360,630
Stock-based compensation
expense
$8,710,302
Accounts payable
$1,465,073
Accrued expenses and
other current...
$796,544
Costs paid in
connection with private...
$90,875
Payment of deferred
offering costs
$30,000
Net cash used in
investing activities
-$45,294,104
Net cash used in
operating activities
-$5,427,064
Canceled cashflow
$120,332,549
Purchase of marketable
securities
$45,294,104
Net loss
-$125,404,384
Prepaid expenses and
other current assets
$218,488
Accretion of marketable
securities
$136,741
Back
Back
Cash Flow
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)
source: myfinsight.com